These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Use of biomarkers in clinical trials and future developments that will help identify novel biomarkers. Malaspina A Int Rev Neurobiol; 2024; 176():171-207. PubMed ID: 38802175 [TBL] [Abstract][Full Text] [Related]
8. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Lyon M; Moore DH Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806 [TBL] [Abstract][Full Text] [Related]
9. Progress, development, and challenges in amyotrophic lateral sclerosis clinical trials. Ashhurst JF; Tu S; Timmins HC; Kiernan MC Expert Rev Neurother; 2022; 22(11-12):905-913. PubMed ID: 36543326 [TBL] [Abstract][Full Text] [Related]
10. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis? de Carvalho M; Swash M Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769 [TBL] [Abstract][Full Text] [Related]
11. Model-Based and Model-Free Techniques for Amyotrophic Lateral Sclerosis Diagnostic Prediction and Patient Clustering. Tang M; Gao C; Goutman SA; Kalinin A; Mukherjee B; Guan Y; Dinov ID Neuroinformatics; 2019 Jul; 17(3):407-421. PubMed ID: 30460455 [TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
13. Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression. Karanevich AG; Statland JM; Gajewski BJ; He J BMC Med Res Methodol; 2018 Feb; 18(1):19. PubMed ID: 29409450 [TBL] [Abstract][Full Text] [Related]
14. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Witzel S; Frauhammer F; Steinacker P; Devos D; Pradat PF; Meininger V; Halbgebauer S; Oeckl P; Schuster J; Anders S; Dorst J; Otto M; Ludolph AC Transl Neurodegener; 2021 Aug; 10(1):31. PubMed ID: 34433481 [TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial. Lombardo FL; Spila Alegiani S; Mayer F; Cipriani M; Lo Giudice M; Ludolph AC; McDermott CJ; Corcia P; Van Damme P; Van den Berg LH; Hardiman O; Nicolini G; Vanacore N; Dickie B; Albanese A; Puopolo M; Trials; 2023 Dec; 24(1):792. PubMed ID: 38053196 [TBL] [Abstract][Full Text] [Related]
19. Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism. Mehta P; Raymond J; Han MK; Larson T; Berry JD; Paganoni S; Mitsumoto H; Bedlack RS; Horton DK J Med Internet Res; 2021 Dec; 23(12):e28021. PubMed ID: 34878988 [TBL] [Abstract][Full Text] [Related]
20. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Jaiswal MK Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]